Cargando…

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in Hodgkin lymphoma. In this phase II study we assessed the safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Den Neste, Eric, André, Marc, Gastinne, Thomas, Stamatoullas, Aspasia, Haioun, Corinne, Belhabri, Amine, Reman, Oumedaly, Casasnovas, Olivier, Ghesquieres, Hervé, Verhoef, Gregor, Claessen, Marie-José, Poirel, Hélène A., Copin, Marie-Christine, Dubois, Romain, Vandenberghe, Peter, Stoian, Ioanna-Andrea, Cottereau, Anne S., Bailly, Sarah, Knoops, Laurent, Morschhauser, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927969/ https://www.ncbi.nlm.nih.gov/pubmed/29351986 http://dx.doi.org/10.3324/haematol.2017.180554

Ejemplares similares

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
por: Smith, Paul, et al.
Publicado: (2021)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis
por: Overstreet, A.M., et al.
Publicado: (2018)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
por: Cattalini, Marco, et al.
Publicado: (2021)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
por: Lap, Coen J., et al.
Publicado: (2021)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway
por: Liao, Xiong-Yu, et al.
Publicado: (2023)

ROCKing the JAKs
por: Peelman, Frank, et al.
Publicado: (2013)

The Jak Tree
Publicado: (1889)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Full Response of a Localized Renal Tumour after Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation
por: Gac, Anne-Claire, et al.
Publicado: (2009)

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2(V617F)-positive myeloproliferative neoplasms
por: de Melo Campos, Paula, et al.
Publicado: (2016)

Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor Ruxolitinib
por: Sobotta, Svantje, et al.
Publicado: (2017)

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
por: Stover, Daniel G., et al.
Publicado: (2018)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F(+) cell models
por: De Marinis, Elisabetta, et al.
Publicado: (2019)

Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis
por: Li, Xia, et al.
Publicado: (2021)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms
por: Courdy, Charly, et al.
Publicado: (2023)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
por: Akiyama, Hiroki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nr4pk1phb3l26p85tkhho91bui